Literature DB >> 22639288

Abnormalities in muscle density and muscle function in hypophosphatemic rickets.

Louis-Nicolas Veilleux1, Moira Cheung, Mouna Ben Amor, Frank Rauch.   

Abstract

CONTEXT: Animal studies suggest that hypophosphatemic rickets (HPR) is associated with muscle function deficits, but it is unknown whether humans with HPR have a muscle disorder.
OBJECTIVE: Our objective was to assess calf muscle size and density (an indicator of muscle quality) and lower extremity muscle function in patients with HPR.
SETTING: The study was carried out in the outpatient department of a pediatric orthopedic hospital. PATIENTS AND OTHER PARTICIPANTS: Participants included 34 individuals with HPR (6-60 yr; nine males) and 34 age- and gender-matched controls. MAIN OUTCOME MEASURES: Calf muscle parameters (muscle cross-sectional area and density) were measured by peripheral quantitative computed tomography. Lower extremity muscle function (peak force per body weight and peak power per body mass) was measured by jumping mechanography through five tests with different levels of difficulty: multiple two-legged hopping, multiple one-legged hopping, single two-legged jump, chair-rise test, and heel-rise test.
RESULTS: Compared with age- and gender-matched controls, patients with HPR had normal muscle size (P = 0.58) but lower muscle density (P = 0.008) and lower peak muscle force and power (P < 0.001 in each test). Muscle function tests were also lower in the subgroup of patients with straight legs (n = 13) than in controls, even though patients with straight legs had higher muscle function test results than patients with severe leg deformities.
CONCLUSIONS: The present study suggests that muscle weakness is a clinical feature of HPR. Lower muscle quality and limb deformities contribute to this functional deficit.

Entities:  

Mesh:

Year:  2012        PMID: 22639288     DOI: 10.1210/jc.2012-1336

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

2.  Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility.

Authors:  Keith G Avin; Julian A Vallejo; Neal X Chen; Kun Wang; Chad D Touchberry; Marco Brotto; Sarah L Dallas; Sharon M Moe; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-20       Impact factor: 4.310

Review 3.  Pharmacological management of X-linked hypophosphataemia.

Authors:  Erik A Imel; Kenneth E White
Journal:  Br J Clin Pharmacol       Date:  2018-10-29       Impact factor: 4.335

4.  Increased Probability of Co-Occurrence of Two Rare Diseases in Consanguineous Families and Resolution of a Complex Phenotype by Next Generation Sequencing.

Authors:  Dennis Lal; Bernd A Neubauer; Mohammad R Toliat; Janine Altmüller; Holger Thiele; Peter Nürnberg; Clemens Kamrath; Anne Schänzer; Thomas Sander; Andreas Hahn; Michael Nothnagel
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

5.  Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets.

Authors:  Michael J Wacker; Chad D Touchberry; Neerupma Silswal; Leticia Brotto; Chris J Elmore; Lynda F Bonewald; Jon Andresen; Marco Brotto
Journal:  Front Physiol       Date:  2016-05-13       Impact factor: 4.566

6.  Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.

Authors:  Mary D Ruppe; Xiaoping Zhang; Erik A Imel; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey S Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Munro Peacock; Thomas O Carpenter
Journal:  Bone Rep       Date:  2016-05-13

7.  Muscle power in children, youth and young adults who acquired HIV perinatally.

Authors:  Η Μ Macdonald; L Nettlefold; E J Maan; H Côté; A Alimenti
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-06-01       Impact factor: 2.041

8.  Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH).

Authors:  Adalbert Raimann; Sarah N Mehany; Patricia Feil; Michael Weber; Peter Pietschmann; Andrea Boni-Mikats; Radka Klepochova; Martin Krššák; Gabriele Häusler; Johannes Schneider; Janina M Patsch; Kay Raum
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-09       Impact factor: 5.555

9.  The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey.

Authors:  Alison Skrinar; Melita Dvorak-Ewell; Ayla Evins; Carolyn Macica; Agnès Linglart; Erik A Imel; Christina Theodore-Oklota; Javier San Martin
Journal:  J Endocr Soc       Date:  2019-05-07

10.  Hypophosphatemia promotes lower rates of muscle ATP synthesis.

Authors:  Dominik H Pesta; Dimitrios N Tsirigotis; Douglas E Befroy; Daniel Caballero; Michael J Jurczak; Yasmeen Rahimi; Gary W Cline; Sylvie Dufour; Andreas L Birkenfeld; Douglas L Rothman; Thomas O Carpenter; Karl Insogna; Kitt Falk Petersen; Clemens Bergwitz; Gerald I Shulman
Journal:  FASEB J       Date:  2016-06-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.